NewMed's funds invest in innovative, development stage companies that have the potential to achieve exceptional growth driven by innovative products. Portfolio companies typically develop improved therapeutics, diagnostics or devices for the treatment of medical needs that are currently unmet of poorly served. We are particularly interested in therapeutic areas where recent breakthroughs permit new approaches to drug development for the NeoMed's funds invest in innovative, development stage companies that have the potential to achieve exceptional growth driven by innovative products. Portfolio companies typically develop improved therapeutics, diagnostics or devices for the treatment of medical needs that are currently unmet of poorly served. We are particularly interested in therapeutic areas where recent breakthroughs permit new approaches to drug development for the treatment of cancer, cardiovascular diseases, neurological diseases and infectious diseases.
NeoMed manages four specialized investment funds:
|
NeoMed I:
|
NeoMed Investments, British Virgin Islands
|
(1997)
|
|
NeoMed II:
|
NeoMed Innovation ASA, Oslo
|
(1998)
|
|
NeoMed III:
|
NeoMed Innovation III L.P., Jersey
|
(2001)
|
|
NeoMed IV:
|
NeoMed Innovation IV L.P., Jersey
|
(2005)
|
The NeoMed team has extensive experience in developing and investing in healthcare life sciences companies. This includes Research and Development, business development, marketing and sales in international diagnostics and pharmaceutical companies. The team is supported by a strong international group of highly respected scientific advisors.
NeoMed operates from offices in Oslo, Geneva and New York, and invests primarily in emerging companies in Europe and North America. We take an active role in the development of our portfolio companies, as a lead investor in Scandinavia or Switzerland, or as an active syndicate member elsewhere.
Website: www.neomed.no
Höegh Capital Partners
NeoMed
